论文部分内容阅读
目的:异基因造血干细胞移植(Allo-HSCT)患者移植前后血浆中IL-17、IL-23浓度与急性移植物抗宿主病(acute graft versus host disease,aGVHD)相关性分析。方法:采用双夹心酶联免疫吸附法(ELISA)检测患者血清中IL-17和IL-23浓度,采用逆转录聚合酶链反应法(Realtime-PCR)检测IL-17mRNA和IL-2mRNA相对表达量。结果:1)移植后aGVHD阴性组和aGVHD阳性组患者在性别、年龄、疾病类型、组织类型和预处理方案差异均无统计学意义,P>0.05。2)各组血浆中IL-17与IL-23浓度检测结果,aGVHD阳性组IL-17的浓度为(330.0±11.5)ρg/mL,显著高于对照组的(109.6±7.6)ρg/mL和aGVHD阴性组的(243.1±16.4)ρg/mL,P值均<0.001;aGVHD阳性组IL-23的浓度为(250.6±14.3)ρg/mL,显著高于对照组的(101.5±9.6)ρg/mL和aGVHD阴性组的(111.0±16.3)ρg/mL,P值均<0.001。3)aGVHD阳性组血浆中IL-17与IL-23浓度检测结果,aGVHD发生当天血浆中IL-17的浓度为(330.0±11.5)ρg/mL,IL-23的浓度为(250.6±14.3)ρg/mL,显著高于aGVHD发生前2周和aGVHD发生后1、2和3周IL-17和IL-23的浓度,P值均<0.05。IL-17、IL-23的浓度在aGVHD发生当天达到高峰,随着症状的控制,逐渐下降。4)aGVHD阳性患者IL-17mRNA的相对表达量为,3.232±1.137,显著高于对照组的1.432±0.954和aGVHD阴性组的1.672±0.896,P值均<0.001;aGVHD阳性患者IL-23mRNA的相对表达量为2.142±1.194,显著高于对照组的1.242±0.752和aGVHD阴性组的1.496±0.653,P值均<0.001。结论:Allo-HSCT后血浆中IL-17、IL-23与aGVHD的发生呈正相关,动态检测allo-HSCT后IL-17和IL-23浓度的变化,可能为临床上预测或诊断aGVHD的发生提供预警或依据。
Objective: To study the correlation between plasma IL-17 and IL-23 levels and acute graft versus host disease (aGVHD) in allo-HSCT patients before and after transplantation. Methods: Serum levels of IL-17 and IL-23 were detected by double-sandwich enzyme-linked immunosorbent assay (ELISA). The relative expression of IL-17 mRNA and IL-2 mRNA was detected by Realtime-PCR . Results: 1) There was no significant difference in gender, age, disease type, tissue type and pretreatment regimen between aGVHD negative group and aGVHD positive group after transplantation (P> 0.05) The concentration of IL-17 in the aGVHD positive group was (330.0 ± 11.5) ρg / mL, which was significantly higher than that in the control group (109.6 ± 7.6 ρg / mL) and the aGVHD negative group (243.1 ± 16.4 ρg / mL and P <0.001 respectively. The concentration of IL-23 in the aGVHD positive group was (250.6 ± 14.3) ρg / mL, which was significantly higher than that in the control group (101.5 ± 9.6) ρg / mL and the aGVHD negative group (111.0 ± 16.3) The plasma levels of IL-17 and IL-17 in the aGVHD positive group were (330.0 ± 11.5) ρg / mL and IL- 23 concentrations of (250.6 ± 14.3) ρg / mL were significantly higher than those of 2 weeks before aGVHD and 1, 2 and 3 weeks after aGVHD, both P <0.05. The concentrations of IL-17 and IL-23 peaked on the day of aGVHD and gradually decreased with symptom control. 4) The relative expression of IL-17mRNA in aGVHD positive patients was 3.232 ± 1.137, significantly higher than that of control group (1.432 ± 0.954) and aGVHD negative group (1.672 ± 0.896), both P <0.001; aGVHD positive patients relative IL-23mRNA The expression level was 2.142 ± 1.194, significantly higher than 1.242 ± 0.752 in the control group and 1.496 ± 0.653 in the aGVHD negative group (P <0.001). CONCLUSIONS: The levels of IL-17, IL-23 and aGVHD in plasma after Allo-HSCT are positively correlated. The dynamic changes of IL-17 and IL-23 after allo-HSCT can be clinically predicted or diagnosed aGVHD Early warning or basis.